The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | The impact of immunotherapy and checkpoint inhibition in treating HCC
Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Republic of Korea, discusses the impact of immune checkpoint inhibitors on the outcomes of patients with hepatocellular carcinoma (HCC). Treatment combinations such as atezolizumab and bevacizumab, as well as durvalumab and tremelimumab have improved outcomes and quality of life in patients with HCC. Trans arterial chemoembolization (TACE) and radiotherapy additionally have a synergistic effect in patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
